Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,112 matching trials from the live ClinicalTrials.gov search.
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Interventions
Optional Blood Sample and Nail Sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
26
States / cities
Duarte, California • San Diego, California • San Francisco, California + 20 more
Conditions
Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal, Cancer Gynecologic, Cancer, Genito-Urinary, Cancers Lymphatic, Cancer Head and Neck
Interventions
Registry - Observational
Device
Lead sponsor
RefleXion Medical
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Duarte, California • Palo Alto, California • New Haven, Connecticut + 2 more
Recruiting Not applicable Interventional

Treatment of Brain AVMs (TOBAS) Study

NCT02098252
Conditions
Unruptured Brain Arteriovenous Malformation, Ruptured Brain Arteriovenous Malformation, Arteriovenous Malformations, AVM, BAVM
Interventions
Neurosurgery, Radiation therapy, Embolization
Procedure · Radiation
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
5 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2036
U.S. locations
3
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico
Conditions
Chest Pain
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
MitraClip® implant
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
38
States / cities
Los Angeles, California • Mountain View, California • Sacramento, California + 31 more
Conditions
Coronary; Ischemic
Interventions
CardioFlux Magnetocardiography
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Kettering, Ohio
Terminated No phase listed Observational

Multiple Myeloma Patient Registry

NCT03180853
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
69
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 63 more
Terminated Not applicable Interventional

Trusted Messenger Intervention

NCT05167422
Conditions
Vaccine Hesitancy
Interventions
Trusted Messenger
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Concord, New Hampshire
Conditions
Breast Cancer
Interventions
MammaPrint 70-gene expression profile, BluePrint 80 gene expression profile
Other
Lead sponsor
Agendia
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
76
States / cities
Glendale, Arizona • Scottsdale, Arizona • Berkeley, California + 67 more
Conditions
Urge Incontinence, Urinary Retention
Interventions
Device Medtronic InterStim Tined Leads Models 3889 and 3093
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
16 Years and older
Enrollment
153 participants
Timeline
2004 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Minneapolis, Minnesota
Completed No phase listed Observational

A Registry for Patients Taking Uptravi

NCT03278002
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Conditions
Cancer, Cancer Risk
Interventions
Biological specimen collection
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
47,500 participants
Timeline
2016 – 2037
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS), Muckle-wells Syn (MWS), Neonatal Onset Multisystem Inflam Disease (NOMID)
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Little Rock, Arizona • Columbus, Georgia • Chicago, Illinois
Active, not recruiting Not applicable Interventional

TRISCEND II Pivotal Trial

NCT04482062
Conditions
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
Interventions
Edwards EVOQUE System, Optimal Medical Therapy
Device · Drug
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more
Conditions
Ventral Hernia, Incisional Hernia
Interventions
Mesh placement with Transfascial Sutures
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Completed No phase listed Observational Results available

Disrupt CAD III Post-Approval Study (PAS)

NCT05021757
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Shockwave C2 Coronary IVL
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Enrolling by invitation No phase listed Observational

Okami Medical ALPHA Registry

NCT07525518
Conditions
Arterial Bleed, Pulmonary Arteriovenous Malformation, Embolization, Hemorrhage
Interventions
LOBO Vascular Occlusion System
Device
Lead sponsor
Okami Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Aurora, Colorado • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Conditions
Movement Disorders, Neurology, Parkinsons Disease
Interventions
Exablate Pallidotomy, Unilateral
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
Conditions
Peripheral Arterial Disease, Quality of Life, Quality of Care
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
21 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • New Orleans, Louisiana + 5 more
Conditions
Hunter Syndrome
Interventions
Elaprase for intravenous (IV) infusion
Drug
Lead sponsor
Shire
Industry
Eligibility
Up to 5 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational

Neurogenetics Patient Registry

NCT02995538
Conditions
Neurogenetic Disorders
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Atrial Fibrillation
Interventions
Patients with Atrial Fibrillation
Other
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
21 Years and older
Enrollment
13,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
217
States / cities
Cullman, Alabama • Dothan, Alabama • Fairhope, Alabama + 214 more
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
Celecoxib, Routine Medical Care
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio